Health-related quality-of-life improvements in CIDP with immune globulin IV 10%
- 14 April 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 72 (15), 1337-1344
- https://doi.org/10.1212/wnl.0b013e3181a0fd80
Abstract
Background: Chronic inflammatory demyelinating polyradiculoneuropathy trials have demonstrated the efficacy of IV immunoglobulin vs placebo. However, these trails have not addressed the long-term impact on health-related quality of life (HRQoL). Methods: One hundred seventeen patients in a randomized, double-blind, response-conditional crossover trial received immune globulin IV, 10% caprylate/chromatography purified (IGIV-C [Gamunex®]), or placebo every 3 weeks for up to 24 weeks in the first period (FP). Participants whose inflammatory neuropathy cause and treatment disability score did not improve by ≥1 point received alternate treatment in a 24-week crossover period (CP). In either period, participants who improved and completed treatment were eligible to be randomly reassigned to a blinded 24-week extension phase (EP). HRQoL analyses were conducted using the Short Form-36® (SF-36) and the Rotterdam Handicap Scale (RHS). Results: In the FP, greater improvements in both SF-36 physical and mental component scores were observed with IGIV-C vs placebo, with a significant improvement in the physical component score (difference 4.4 points; 95% confidence interval [CI] 0.7–8.0). Improvements in all SF-36 domains favored IGIV-C vs placebo, with physical functioning, role–physical, social functioning, and mental health reaching significance. Participants receiving IGIV-C experienced a larger improvement in RHS vs those receiving placebo (difference 3.4 points; 95% CI 1.4–5.5; p = 0.001). In the CP, similar general trends were observed. In the EP, mean SF-36 improvements were generally improved or maintained in participants who continued IGIV-C therapy; however, worsening was observed in participants re-randomized to placebo. Conclusions: Long-term therapy with immune globulin IV, 10% caprylate/chromatography purified, improves and maintains health-related quality of life in chronic inflammatory demyelinating polyradiculoneuropathy.Keywords
This publication has 18 references indexed in Scilit:
- Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in ItalyJournal of Neurology, Neurosurgery & Psychiatry, 2007
- 131st ENMC International workshop: Selection of Outcome Measures for Peripheral Neuropathy Clinical Trials: 10–12 December 2004, Naarden, The NetherlandsNeuromuscular Disorders, 2006
- Intravenous Immunoglobulin Treatment in Autoimmune Neurological Disorders—Effects on Quality of LifeHuman Immunology, 2005
- Chronic Inflammatory Demyelinating PolyneuropathyNew England Journal of Medicine, 2005
- Cost–utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathyEuropean Journal of Neurology, 2003
- Psychometric evaluation of a new handicap scale in immune‐mediated polyneuropathiesMuscle & Nerve, 2002
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001
- Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathiesNeurology, 2000
- Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- High‐dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathyNeurology, 1990